30 closest matches · ranked by relevance
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Myocardial Infarction
Primary: LogEC50 Platelet Aggregation — 2.65; 2.62 nM
Myocardial Infarction
Primary: Concentration of Platelet Extracellular Vesicles/ml — 2690000; 4310000 Platelet Extracellular Vesicles/mL
Acute ST Segment Elevation Myocardial Infarction
Primary: Platelet Inhibition Measured With Optical Aggregometry — 109; 253.8 AU*min
HIV · Cardiovascular Diseases · Inflammation
Primary: Percentage Platelet Aggregation in PRP After Stimulation With Arachidonic Acid 1600 μM for 5 Min — 72.35; 79.11; 72.79; 26.77 %aggregation
PRU(Platelet Reactivity Unit) · APT(Antiplatelet Therapy) · HOTPR(High on Treat Platelet Reactivity)
Primary: Numbers of Participants With MACE(Major Adverse Cardiac Event) of Study Subjects — 1; 1; 2 numbers of participants with MACE — p=0.002
Subarachnoid Hemorrhage, Aneurysmal
Primary: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) — 2; 1 Participants
Coronary Artery Disease
Primary: Change From Baseline in ADP-mediated Platelet Aggregation, APP, SFFLRN, AYPGKF. — 84; 38; 94; 53 % inhibitn of platelet aggregation — p=0.001
Stroke · Myocardial Infarctions
Primary: PFA1 — 202.0; 271.1; 234.7 seconds — p=0.0742
HIV-1 Infection
Primary: Change in sCD14 From Baseline to Week 24 — 35.75; -251.40; -101.75 pg/mL
Diabetes Mellitus With Hypoglycemia · Diabetes Mellitus, Type 2 · Hypoglycemia
Primary: Changes in Platelet Activation Marker Adenosin Diphosphate (%) — 63; 64.4; 64.4; 61.1 percentage of ADP
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
Blood Platelets · Clopidogrel
Primary: Change From Baseline in Platelet Surface Activated GPIIb-IIIa Complex at 45 Days After Intervention. — 123.2; 126.7 mean fluorescence intensity (MFI)
Stable Angina
Primary: PRU(Platelet Rreactivity Unit) 24 Hours After DAPT(Dual AntiPlatelet Therapy) Western Blot After Medication — 148; 289; 79; 132 PRU(Platelet Rreactivity Unit)
Heart Attack
Primary: Pharmacodynamic Assessment of Degree of Platelet Inhibition as Determined by Verify Now Point of Care Assay and Expressed as P2Y12 Reaction Units (PRU) — 270.23; 247.73…
Obstetric Labor Complications · Preeclampsia · Thrombocytopenia
Primary: Positive Predictive Value of Earliest Available Platelet Count — 99; 90; 100 percentage of positive platelet counts
Coronary Artery Disease
Primary: Platelet Reactivity Index (PRI) Determined by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP) — 30; 30; 18; 17 %PRI
Healthy Volunteers
Primary: Number of Participants With Platelet Units Containing an Acceptable Residual WBC Level — 93; 93; 93; 0 Participants
Healthy Volunteers
Primary: Number of Participants With Platelet Units Containing an Acceptable Residual WBC Level — 92; 93; 93; 1 Participants
STEMI · NSTEMI
Primary: Ischemic — 2.09; 2.71; 3.24; 2.57 Hazard Ratio comparing high and low pFCG
Coronary Artery Disease · Peripheral Vascular Disease · Myocardial Infarction
Primary: Effects of Vorapaxar on 15 μmol/L SFLLRN (PAR-1 Activating Peptide) Induced Platelet Aggregation — 8; 5; 5; 4 Maximum aggregation (%)
Thrombocytopenia · Hematologic Diseases · Bone Marrow Aplasia
Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants
Aortic Stenosis · Inflammation · Thrombosis
Primary: Platelet Reactivity — 275.5; 251; 234; 128.5 Platelet Reactivity Units
Healthy Volunteers
Primary: pH of Platelets at Day 5 — 7.184; 7.414 pH
PRU · miRNA
Primary: miRNA — -8.14; -3.46; -7.54; -3.97 fold of change
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 284.1; 284.1; 39.1; 37.5 PRU
Intracerebral Hemorrhage
Primary: Change in Platelet Activity, Measured in Seconds on PFA-EPI Assay, From Pre to Post-treatment — 68 seconds — p=0.014
Stable Coronary Artery Disease
Primary: Proportion of Clopidogrel Non-responders Who Responded to Clopidogrel or Ticagrelor. - Comparing Ticag. (Day 28 of Clop. to Ticag., and Day 14 of Ticag. to Clop.) Versus…
Essential Thrombocythemia (ET)
Primary: Percentage of Subjects Who Responded in Platelet Count — 67.9 percentage of subjects